Rare Blood Cancer BPDCN Gets a New ADC Option as FDA Approves AbbVie’s DECNUPAZ

For patients with rare cancers, treatment progress is often not a neat curve from large-scale trials, but the gradual accumulation of usable clinical options amid limited patient numbers, complex disease courses, and high uncertainty. AbbVie announced on May 27 that the U.S. Food and Drug Administration has approved DECNUPAZ (pivekimab sunirine-pvzy) for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive hematologic malignancy.

BPDCN often begins with or is noticed through skin lesions, but the disease can rapidly invade the bone marrow, lymph nodes, and even the central nervous system. Existing treatment has historically relied largely on more intensive chemotherapy, with some patients going on to receive stem cell transplantation; however, relapse is not uncommon, and for older patients there is often a difficult trade-off between treatment tolerability and disease control.

DECNUPAZ is an antibody-drug conjugate (ADC) that targets CD123. The basic concept behind this type of medicine is to use an antibody to recognize a relatively prominent marker on the surface of cancer cells, then deliver a cytotoxic drug payload into the target cell. AbbVie said BPDCN cells often highly express CD123, making it the central target of this drug design; this approval also marks AbbVie’s first ADC approved for use in blood cancer.

The main data supporting the approval came from the Phase 1/2 CADENZA trial. ClinicalTrials.gov registration records show that the study number is NCT03386513, and that the drug evaluated had previously been developed under the name IMGN632, enrolling patients with untreated and relapsed or refractory BPDCN. This helps connect the drug’s early development name, trial registration information, and the clinical evidence cited for this approval.

According to data released by AbbVie, among 33 newly diagnosed BPDCN patients treated with DECNUPAZ, the composite complete response rate was 69.7%, and the median duration of response was 9.7 months; 13 of these patients subsequently were able to receive stem cell transplantation. Among 51 patients with relapsed or refractory disease, the composite complete response rate was 15.7%, the median duration of response was 9.2 months, and 6 patients subsequently received transplantation. These figures suggest a clearer signal for the drug in the first-line population, but both patient groups were small, and the results cannot be directly equated with a long-term survival benefit.

Safety remains a key boundary as this treatment enters clinical practice. DECNUPAZ carries a boxed warning for hepatotoxicity, including the potential occurrence of hepatic veno-occlusive disease; common adverse reactions include edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea. For a rare and rapidly progressing cancer, the efficacy signal carries weight, but risk monitoring and patient selection will likewise shape its position in the real world.

This approval also reflects the realities of drug development for rare blood cancers: studies often struggle to reach the scale of large randomized trials, and clinical decision-making must balance small samples, open-label studies, and urgent medical need. DECNUPAZ adds a new option with a clear molecular target for adult patients with BPDCN; the extent to which it can change treatment sequencing, transplantation strategies, and post-relapse care will still need to be answered through subsequent clinical use and longer-term data.